Advertisement

Clinical and Translational Oncology

, Volume 17, Issue 6, pp 431–437 | Cite as

CMTM5 is reduced in prostate cancer and inhibits cancer cell growth in vitro and in vivo

  • Y. Xiao
  • Y. Yuan
  • Y. ZhangEmail author
  • J. Li
  • Z. Liu
  • X. Zhang
  • Z. Sheng
  • T. XuEmail author
  • X. Wang
Research Article

Abstract

Purpose

A novel tumor suppressor CKLF-like MARVEL transmembrane domain-containing member 5 (CMTM5) is reduced or undetectable in many kinds of cancers and inhibits tumor cells’ malignant features. To explore its role in prostate cancer (PCa), we detected its expression patterns in prostate tissues and PCa cells, and determined its anti-proliferation functions in PCa cells in vitro and in vivo.

Methods

The expression of CMTM5 in prostate tissue microarray, specimens and cell lines was evaluated by immunohistochemistry and Western blot, respectively. After being transfected with CMTM5 adenovirus or vector, the proliferation and migration of DU145 cells were detected by MTT assay and transwell assay, respectively. Furthermore, the effects of CMTM5 on tumor growth were performed in nude mice xenograft in vivo.

Results

We found CMTM5 was reduced in PCa tissues and cells compared with BPH tissues, and its expression in PCa tissues was related to the Gleason score. Moreover, after being transfected with adenovirus, ectopic expression of CMTM5-v1 in DU145 cells led to significant inhibition of cell proliferation and migration compared with the control, which may be attributed to decreased Akt activity. Finally, restoration of CMTM5 significantly suppressed tumor growth in vivo.

Conclusions

These results indicate that CMTM5 is down-regulated in PCa and exhibit tumor suppressor activities in androgen-independent PCa cells. Loss of CMTM5 protein may be contributed to the development of PCa and it is a potential therapeutic target for castration-resistant prostate cancer.

Keywords

CMTM5 Prostate cancer TM4SF Tumor suppressor gene Gene therapy 

Notes

Acknowledgments

This work was supported by the National Natural Science Foundation of China (NSFC) 81072099. We thank Drs. Wenling Han for her generous offer of adenovirus vector and antibody. We also thank Weidong Yu, Yidong Niu and Henan Li for some technical support, and Jianqiang Dong and the Department of Pathology, Peking University People’s Hospital for support for IHC and staining evaluation.

Conflict of interest

The authors declare no conflict of interest.

References

  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.PubMedGoogle Scholar
  2. 2.
    Loblaw DA, Mendelson DS, Talcott JA, Virgo KS, Somerfield MR, Ben-Josef E, et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol. 2004;22(14):2927–41.PubMedGoogle Scholar
  3. 3.
    Marques RB, Dits NF, Erkens-Schulze S, van Weerden WM, Jenster G. Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models. PLoS ONE. 2010;5(10):e13500.CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009;6(2):76–85.PubMedCentralPubMedGoogle Scholar
  5. 5.
    Han W, Ding P, Xu M, Wang L, Rui M, Shi S, et al. Identification of eight genes encoding chemokine-like factor superfamily members 1–8 (CKLFSF1–8) by in silico cloning and experimental validation. Genomics. 2003;81(6):609–17.CrossRefPubMedGoogle Scholar
  6. 6.
    Zhong J, Wang Y, Qiu X, Mo X, Liu Y, Li T, et al. Characterization and expression profile of CMTM3/CKLFSF3. J Biochem Mol Biol. 2006;39(5):537–45.PubMedGoogle Scholar
  7. 7.
    Wang Y, Zhang Y, Yang X, Han W, Liu Y, Xu Q, et al. Chemokine-like factor 1 is a functional ligand for CC chemokine receptor 4 (CCR4). Life Sci. 2006;78(6):614–21.PubMedGoogle Scholar
  8. 8.
    Shi S, Rui M, Han W, Wang Y, Qiu X, Ding P, et al. CKLFSF2 is highly expressed in testis and can be secreted into the seminiferous tubules. Int J Biochem Cell Biol. 2005;37(8):1633–40.PubMedGoogle Scholar
  9. 9.
    Wang Y, Li J, Cui Y, Li T, Ng KM, Geng H, et al. CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. Cancer Res. 2009;69(12):5194–201.PubMedGoogle Scholar
  10. 10.
    Jin C, Ding P, Wang Y, Ma D. Regulation of EGF receptor signaling by the MARVEL domain-containing protein CKLFSF8. FEBS Lett. 2005;579(28):6375–82.PubMedGoogle Scholar
  11. 11.
    Wang Y, Li T, Qiu X, Mo X, Zhang Y, Song Q, et al. CMTM3 can affect the transcription activity of androgen receptor and inhibit the expression level of PSA in LNCaP cells. Biochem Biophys Res Commun. 2008;371(1):54–8.PubMedGoogle Scholar
  12. 12.
    Shao L, Li T, Mo X, Majdic O, Zhang Y, Seyerl M, et al. Expressional and functional studies of CKLF1 during dendritic cell maturation. Cell Immunol. 2010;263(2):188–95.PubMedGoogle Scholar
  13. 13.
    Plate M, Li T, Wang Y, Mo X, Zhang Y, Ma D, et al. Identification and characterization of CMTM4, a novel gene with inhibitory effects on HeLa cell growth through Inducing G2/M phase accumulation. Mol Cells. 2010;29(4):355–61.PubMedGoogle Scholar
  14. 14.
    Hemler ME. Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Annu Rev Cell Dev Biol. 2003;19:397–422.PubMedGoogle Scholar
  15. 15.
    Hatta M, Nagai H, Okino K, Onda M, Yoneyama K, Ohta Y, et al. Down-regulation of members of glycolipid-enriched membrane raft gene family, MAL and BENE, in cervical squamous cell cancers. J Obstet Gynaecol Res. 2004;30(1):53–8.PubMedGoogle Scholar
  16. 16.
    Sridhar SC, Miranti CK. Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases. Oncogene. 2006;25(16):2367–78.CrossRefPubMedGoogle Scholar
  17. 17.
    Mimori K, Shiraishi T, Mashino K, Sonoda H, Yamashita K, Yoshinaga K, et al. MAL gene expression in esophageal cancer suppresses motility, invasion and tumorigenicity and enhances apoptosis through the Fas pathway. Oncogene. 2003;22(22):3463–71.CrossRefPubMedGoogle Scholar
  18. 18.
    Liu WM, Zhang XA. KAI1/CD82, a tumor metastasis suppressor. Cancer Lett. 2006;240(2):183–94.PubMedGoogle Scholar
  19. 19.
    Cheng Y, Ko JM, Lung HL, Lo PH, Stanbridge EJ, Lung ML. Monochromosome transfer provides functional evidence for growth-suppressive genes on chromosome 14 in nasopharyngeal carcinoma. Genes Chromosomes Cancer. 2003;37(4):359–68.PubMedGoogle Scholar
  20. 20.
    Tepel M, Roerig P, Wolter M, Gutmann DH, Perry A, Reifenberger G, et al. Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. Int J Cancer. 2008;123(9):2080–6.PubMedGoogle Scholar
  21. 21.
    Lusis EA, Watson MA, Chicoine MR, Lyman M, Roerig P, Reifenberger G, et al. Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res. 2005;65(16):7121–6.PubMedGoogle Scholar
  22. 22.
    Shao L, Cui Y, Li H, Liu Y, Zhao H, Wang Y, et al. CMTM5 exhibits tumor suppressor activities and is frequently silenced by methylation in carcinoma cell lines. Clin Cancer Res. 2007;13(19):5756–62.PubMedGoogle Scholar
  23. 23.
    Shao L, Guo X, Plate M, Li T, Wang Y, Ma D, et al. CMTM5-v1 induces apoptosis in cervical carcinoma cells. Biochem Biophys Res Commun. 2009;379(4):866–71.PubMedGoogle Scholar
  24. 24.
    Guo X, Li T, Wang Y, Shao L, Zhang Y, Ma D, et al. CMTM5 induces apoptosis of pancreatic cancer cells and has synergistic effects with TNF-alpha. Biochem Biophys Res Commun. 2009;387(1):139–42.PubMedGoogle Scholar
  25. 25.
    Li P, Liu K, Li L, Yang M, Gao W, Feng J, et al. Reduced CMTM5 expression correlates with carcinogenesis in human epithelial ovarian cancer. Int J Gynecol Cancer. 2011;21(7):1248–55.PubMedGoogle Scholar
  26. 26.
    Niu J, Li H, Zhang Y, Li J, Xie M, Li L, et al. Aberrant expression of CKLF-like MARVEL transmembrane member 5 (CMTM5) by promoter methylation in myeloid leukemia. Leuk Res. 2011;35(6):771–6.PubMedGoogle Scholar
  27. 27.
    Zhang H, Nan X, Li X, Chen Y, Zhang J, Sun L, et al. CMTM5 exhibits tumor suppressor activity through promoter methylation in oral squamous cell carcinoma. Biochem Biophys Res Commun. 2014;447(2):304–10.PubMedGoogle Scholar
  28. 28.
    Sasaki T, Ryo A, Uemura H, Ishiguro H, Inayama Y, Yamanaka S, et al. An immunohistochemical scoring system of prolyl isomerase Pin1 for predicting relapse of prostate carcinoma after radical prostatectomy. Pathol Res Pract. 2006;202(5):357–64.PubMedGoogle Scholar
  29. 29.
    Sanchez-Pulido L, Martin-Belmonte F, Valencia A, Alonso MA. MARVEL: a conserved domain involved in membrane apposition events. Trends Biochem Sci. 2002;27(12):599–601.PubMedGoogle Scholar
  30. 30.
    Li H, Li J, Su Y, Fan Y, Guo X, Li L, et al. A novel 3p22.3 gene CMTM7 represses oncogenic EGFR signaling and inhibits cancer cell growth. Oncogene. 2014;33(24):3109–18.CrossRefPubMedGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2014

Authors and Affiliations

  1. 1.Department of UrologyPeking University People’s HospitalBeijingChina
  2. 2.Department of UrologyThe First Affiliated Hospital of Wenzhou Medical UniversityWenzhouChina
  3. 3.Department of Urology, The Second Clinical Medical College of Jinan UniversityShenzhen People’s HospitalShenzhenChina

Personalised recommendations